Intensity Therapeutics Inc (INTS)

Currency in USD
0.418
+0.001(+0.24%)
Closed·
0.410-0.008(-1.91%)
·
INTS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.3670.420
52 wk Range
0.1853.166
Key Statistics
Prev. Close
0.417
Open
0.41
Day's Range
0.367-0.42
52 wk Range
0.185-3.166
Volume
1.92M
Average Volume (3m)
30.31M
1-Year Change
-78.64%
Book Value / Share
0.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
INTS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.917
Upside
+597.77%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Intensity Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Compare INTS to Peers and Sector

Metrics to compare
INTS
Peers
Sector
Relationship
P/E Ratio
−2.1x−2.4x−0.6x
PEG Ratio
−0.040.120.00
Price/Book
3.5x2.9x2.6x
Price / LTM Sales
-193.6x3.2x
Upside (Analyst Target)
-30.5%41.8%
Fair Value Upside
Unlock−4.7%5.1%Unlock

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 2.917
(+597.77% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Benchmark
Buy1.50+258.85%4.00Maintain20/08/2025
Brookline Capital Markets
Buy3.00+617.70%-Upgrade12/08/2025
ThinkEquity
Buy3.00+617.70%-New Coverage28/07/2025
Benchmark
Buy4.00+856.94%4.00Maintain21/05/2025
Brookline Capital Markets
Hold---Downgrade19/05/2025

Earnings

Latest Release
Nov 07, 2025
EPS / Forecast
-0.06 / -0.06
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

0.46
VSEE
+4.49%
1.27
RUBI
-9.29%
1.4600
INHD
-7.59%
2.190
BQ
-0.45%
0.047
VIVK
-24.39%

FAQ

What Is the Intensity Therapeutics (INTS) Share Price Today?

The live Intensity Therapeutics share price today is 0.418

What Stock Exchange Does Intensity Therapeutics (INTS) Trade On?

Intensity Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Intensity Therapeutics?

The stock symbol (also called a 'ticker') for Intensity Therapeutics is "INTS."

What Is the Current Intensity Therapeutics Market Cap?

As of today, Intensity Therapeutics market capitalisation is 25.11M.

What Is Intensity Therapeutics's (INTS) Earnings Per Share (TTM)?

The Intensity Therapeutics EPS is currently -0.51 (Trailing Twelve Months).

When Is the Next Intensity Therapeutics Earnings Date?

Intensity Therapeutics's next earnings report will be released on 12 Mar 2026.

Is INTS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Intensity Therapeutics moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Intensity Therapeutics Stock Split?

Intensity Therapeutics has split 1 times. (See the INTS stock split history page for full effective split date and price information.)

How Many Employees Does Intensity Therapeutics Have?

Intensity Therapeutics has 6 employees.

What is the current trading status of Intensity Therapeutics (INTS)?

As of 24 Dec 2025, Intensity Therapeutics (INTS) is trading at a price of 0.418, with a previous close of 0.417. The stock has fluctuated within a day range of 0.367 to 0.420, while its 52-week range spans from 0.185 to 3.166.

What Is Intensity Therapeutics (INTS) Price Target According to Analysts?

The average 12-month price target for Intensity Therapeutics is USD2.91667, with a high estimate of USD5 and a low estimate of USD1.5. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +597.77% Upside potential.

What Is the INTS Premarket Price?

INTS's last pre-market stock price is 0.411. The pre-market share volume is 95,900.000, and the stock has decreased by -0.006, or -1.440%.

What Is the INTS After Hours Price?

INTS's last after hours stock price is 0.410, the stock has decreased by -0.008, or -1.910%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.